한글목차

약제 요약

VIR-2218은 HBV를 표적으로 하는 피하주사형 siRNA로 효과적인 면역반응을 자극하고 HBV와 HDV에 대한 직접적인 항바이러스 활성을 가지고 있으며, VIR-3218은 안정성을 높이고 오프타깃 활성을 최소화하는 ESC(Enhanced Stabilization Chemistry Plus) 기술을 도입한 최초의 임상용 siRNA로 치료 지수를 높일 수 있는 가능성을 가지고 있습니다.

또한 VIR-3434는 HBV 및 HDV 바이러스가 간세포에 침입하는 것을 막고 혈액내 빌리언 및 하위 바이러스 입자의 수준을 낮추도록 설계된 시험 중인 피하 투여 항체이며, VIR-3434는 Xencor의 Xtend 및 기타 Fc 기술을 통합하고 있으며, 감염된 환자에서 HBV 및 HDV에 대한 T세포 백신으로 작용할 수 있으며, 반감기가 연장되도록 설계되었습니다.

주요 7 시장(미국·독일·프랑스·이탈리아·스페인·영국·일본)의 만성 B형 간염용 VIR-2218+VIR-3434에 대해 조사분석했으며, 작용기서, 용법과 용량, 연구개발 활동에 관한 인사이트, 매출의 예측 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 만성 B형 간염에서 VIR-2218+VIR-3434의 개요

• 제품의 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신치료법)

제5장 VIR-2218+VIR-3434 시장 평가

• 만성 B형 간염에서 VIR-2218+VIR-3434의 시장 전망
• 주요 7 시장 분석
  • 주요 7 시장의 만성 B형 간염용 VIR-2218+VIR-3434의 시장 규모
• 시장 분석 : 국가별
  • 미국의 만성 B형 간염용 VIR-2218+VIR-3434의 시장 규모
  • 독일의 만성 B형 간염용 VIR-2218+VIR-3434의 시장 규모
  • 영국의 만성 B형 간염용 VIR-2218+VIR-3434의 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"VIR-2218 + VIR- 3434 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about VIR-2218 + VIR- 3434 for chronic hepatitis B in the seven major markets. A detailed picture of the VIR-2218 + VIR- 3434 for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VIR-2218 + VIR- 3434 for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VIR-2218 + VIR- 3434 market forecast analysis for chronic hepatitis B in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that can stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include enhanced stabilization chemistry plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index.

Also, VIR-3434 is an investigational subcutaneously administered antibody designed to block the entry of HBV and HDV viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencor's Xtend and other Fc technologies, has been engineered to potentially function as a T-cell vaccine against HBV and HDV in infected patients and to have an extended half-life.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the VIR-2218 + VIR- 3434 description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on VIR-2218 + VIR- 3434 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VIR-2218 + VIR- 3434 research and development activities in chronic hepatitis B across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around VIR-2218 + VIR- 3434.
• The report contains forecasted sales of VIR-2218 + VIR- 3434 for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for VIR-2218 + VIR- 3434 in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VIR-2218 + VIR- 3434 Analytical Perspective by DelveInsight

• In-depth VIR-2218 + VIR- 3434 Market Assessment

This report provides a detailed market assessment of VIR-2218 + VIR- 3434 for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2031 to 2032.

• VIR-2218 + VIR- 3434 Clinical Assessment

The report provides the clinical trials information of VIR-2218 + VIR- 3434 for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VIR-2218 + VIR- 3434 dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to VIR-2218 + VIR- 3434 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VIR-2218 + VIR- 3434 in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of VIR-2218 + VIR- 3434 from 2031 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VIR-2218 + VIR- 3434 in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of VIR-2218 + VIR- 3434?
• What is the clinical trial status of the study related to VIR-2218 + VIR- 3434 in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VIR-2218 + VIR- 3434 development?
• What are the key designations that have been granted to VIR-2218 + VIR- 3434 for chronic hepatitis B?
• What is the forecasted market scenario of VIR-2218 + VIR- 3434 for chronic hepatitis B?
• What are the forecasted sales of VIR-2218 + VIR- 3434 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VIR-2218 + VIR- 3434 for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Table of Contents

1. Report Introduction

2. VIR-2218 + VIR- 3434 Overview in Chronic hepatitis B

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. VIR-2218 + VIR- 3434 Market Assessment

• 5.1. Market Outlook of VIR-2218 + VIR- 3434 in Chronic hepatitis B
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of VIR-2218 + VIR- 3434 in the 7MM for Chronic hepatitis B
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of VIR-2218 + VIR- 3434 in the United States for Chronic hepatitis B
  • 5.3.2. Market Size of VIR-2218 + VIR- 3434 in Germany for Chronic hepatitis B
  • 5.3.3. Market Size of VIR-2218 + VIR- 3434 in France for Chronic hepatitis B
  • 5.3.4. Market Size of VIR-2218 + VIR- 3434 in Italy for Chronic hepatitis B
  • 5.3.5. Market Size of VIR-2218 + VIR- 3434 in Spain for Chronic hepatitis B
  • 5.3.6. Market Size of VIR-2218 + VIR- 3434 in the United Kingdom for Chronic hepatitis B
  • 5.3.7. Market Size of VIR-2218 + VIR- 3434 in Japan for Chronic hepatitis B

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options